Clinical Trials Logo

Other clinical trials

View clinical trials related to Other.

Filter by:

NCT ID: NCT06359860 Recruiting - Clinical trials for Unresectable or Metastatic Melanoma

A Study of ST-1898 for Unresectable or Metastatic Melanoma

Start date: November 7, 2023
Phase: Phase 1/Phase 2
Study type: Interventional

ST-1898 is a receptor tyrosine kinase (RTK) inhibitor for multi-targets, especially for VEGFR2, c-MET, AXL, PDGFRA, RET, KIT etc. This trial is to evaluate its safety, tolerability, pharmacokinetic, and efficacy in subjects with unresectable or metastatic melanoma. In phase Ib, the primary objectives are to assess the safety and tolerability, and to determine Recommended Phase 2 dose (RP2D) of ST-1898 tablets in subjects with unresectable or metastatic melanoma. Secondary objectives are to assess the plasma concentration of ST-1898 and to evaluate the efficacy. In phase II, the primary objective is to assess the anti-tumor activities of ST-1898 tablets in subjects with unresectable or metastatic melanoma. The secondary objective is to evaluate the safety of ST-1898 tablets.

NCT ID: NCT06359808 Recruiting - Colitis, Ulcerative Clinical Trials

Clinical Characteristics of Sleep Disorders in Patients With Ulcerative Colitis

Start date: April 1, 2024
Phase:
Study type: Observational

Ulcerative colitis(UC) is one of the two main forms of inflammatory bowel disease(IBD), which seriously affects the quality of life of patients. Previous studies have demonstrated that more than 60% of IBD patients have sleep disorders, which is emerging as an important risk factor for disease recurrence and poor prognosis. However, the mechanisms by which sleep disorders regulates the occurrence and development of IBD remain undefined. This study aims to explore the clinical characteristics of ulcerative colitis patients with sleep disorders based on the microbiota-gut-brain axis, to analyze the effects of sleep disorders on autonomic nervous function, gut microbiota, and metabolites in UC patients.

NCT ID: NCT06359535 Recruiting - Clinical trials for Nausea and Vomiting, Postoperative

An Economic Study of HSK21542 Injection for Prevention of Postoperative Nausea and Vomiting

Start date: February 23, 2024
Phase: Phase 4
Study type: Interventional

This study analyzed the efficacy and safety results of HSK21542 injection for the prevention of postoperative nausea and vomiting in a multicentre, randomized, double-blind, placebo-controlled dose-exploration study, as well as the real-world clinical routine use of troisisone and other (not limited to other setron drugs) for the prevention of postoperative nausea and vomiting and related adverse reaction treatment data. It was transformed into an effect indicator, and the possible costs involved in the study were analyzed, reasonable price parameters of HSK21542 injection were set, and the economic value of HSK21542 was explored.

NCT ID: NCT06359145 Recruiting - Clinical trials for Pulmonary Disease, Chronic Obstructive

Prediction of COPD Severity Using Electrical Impedance Tomography

Start date: April 1, 2023
Phase:
Study type: Observational

The purpose of this study is to predict the CT visual score of emphysema with EIT-based parameters, in order to provide a non-invasive and convenient method for the evaluation of lung structure and physiological and pathological progression of COPD.

NCT ID: NCT06358248 Recruiting - Aortic Diseases Clinical Trials

Standardized Physician-modified Fenestrated Endograft Registry

SPHERE
Start date: October 1, 2023
Phase:
Study type: Observational

Multicenter retrospective study including all consecutive patients treated by PMEG using a standard modification technique of Valiant Captivia (Medtronic, Minneapolis, MN-USA).

NCT ID: NCT06357598 Recruiting - Clinical trials for Non-small-cell Lung Cancer (NSCLC)

Preoperative Neoadjuvant Immunotherapy Combined With Chemotherapy for Stage Ⅲ Unresectable Non-small Cell Lung Cancer

PILOT
Start date: January 18, 2024
Phase: Phase 4
Study type: Interventional

Explorative study, which evaluates the effect of Tislelizumab combined with chemotherapy in neoadjuvant treatment of stage Ⅲ unresectable non-small-cell lung carcinoma.

NCT ID: NCT06356727 Recruiting - Heart Failure Clinical Trials

Microvascular Dysfunction Assessment to Predict Left Ventricular Reverse Remodeling

MICROREV
Start date: January 3, 2024
Phase: N/A
Study type: Interventional

Patients presenting with idiopathic dilated cardiomyopathy and left ventricle dysfunction (LVEF <40%), naive of anti-remodeling cardiac medical therapy, will undergo invasive coronary microvascular assessment based on thermodilution. The primary endpoint, namely the left ventricle reverse remodeling, will be assessed after 12 months of optimal medical therapy based on transthoracic echocardiography. The primary endpoint will be evaluated by an independent central core lab. Patients enrolled in the study will be followed for a period of 5 years to monitor their clinical status. During the study period participants may undergo multimodality diagnostic tests including ECG telemetry monitoring, cardiopulmonary exercise testing, cardiovascular cardiac magnetic resonance.

NCT ID: NCT06356636 Recruiting - Clinical trials for Health Knowledge, Attitudes, Practice

Impact of the Financial Inclusion Improves Sanitation and Health

FINISH
Start date: January 1, 2022
Phase: N/A
Study type: Interventional

The goal of this interventional study is to evaluate the impacts of Financial Inclusion improvement sanitation and Health (FINISH) interventions in Kenya's Homa Bay County and Uganda's Kamwenge District among children under five. The main questions it aims to answer are: 1. What is the estimated impact of the FINISH model on health outcomes (diarrhoea occurrence and hygienic behaviour) as well as social (school attendance and sanitation) in the intervention groups? 2. What are the perspectives, attitudes, and practices of various stakeholders (communities, governments, entrepreneurs, and financiers) regarding the FINISH model? 3. What is the cost-effectiveness of the FINISH model, including the amount of leverage funds generated? The FINISH model postulates that countries will be supported to improve the enabling business environment for sanitation, markets to offer improved safely managed services and products at an affordable price, and formal and informal financial institutions will offer more funding to businesses and households for satiation and hygiene. Researchers will then compare intervention areas (Homa Bay in Kenya and Kamwenge in Uganda) with control areas (Siaya and Bushenyi in Kenya and Uganda, respectively) to see if the FINISH intervention leads to improved sanitation, health outcomes, and economic benefits.

NCT ID: NCT06356272 Recruiting - Clinical trials for Oropharyngeal Squamous Cell Carcinoma

Oropharynx (OPX) Biomarker Trial

Start date: November 15, 2019
Phase:
Study type: Observational

The purpose of this research is to identify a biomarker that is exists when human papillomavirus (HPV) mediated oropharyngeal squamous cell carcinoma is present and does not exist when HPV mediated oropharyngeal squamous cell carcinoma is absent.

NCT ID: NCT06356090 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

SPACE: a Parent-based Treatment for Pediatric OCD

Start date: November 23, 2023
Phase: N/A
Study type: Interventional

This study will investigate the parent-based treatment SPACE: Supportive Parenting for Anxious Childhood Emotions. The aim of this study is to investigate whether SPACE is effective in reducing family accommodation (FA) and OCD symptoms in children with a complex obsessive-compulsive disorder (OCD), that did not or cannot benefit from first line treatment.